Background Understanding the molecular pathogenesis of distinct phenotypes in human
benign prostatic hyperplasia (BPH) is essential to improving therapeutic intervention …

Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of
glandular epithelial tissue, smooth muscle, and connective tissue within the prostatic …

Objective To correlate patients' perception of changes in their lower urinary tract symptoms
with changes in their American Urological Association Symptom Index (AUA-SI) scores with …

Purpose To investigate the effect of metabolic syndrome (MS) on patient outcomes who
underwent holmium laser enucleation of the prostate (HoLEP) for benign prostatic …

Inhibition of 5α-reductase (5αR), which blocks the conversion of testosterone to its active
metabolite, dihydrotestosterone, has been shown to impact further prostate enlargement …

Benign prostatic hyperplasia (BPH) is most common in men 40 years and above. It rarely
occurs in childhood. As a result of the scarcity of cases, the pathogenesis is not clear, and …

Self-report assessment of lower urinary tract symptoms (LUTS) is complicated by the many
tools that are available. The International Prostate Symptom Score (IPSS) is widely used and …

Заключение. Ультразвуковой показатель ИПП при значении более 10 мм высоко
коррелирует с наличием ИВО у мужчин с СНМП и ДГПЖ по сравнению с другими …

Lower urinary tract symptoms (LUTS) are very common in both sexes, especially in aged
population and negatively affect health-related quality of life of afflicted individuals. The …

Benign prostatic hyperplasia (BPH) can be a progressive disease for some men with
significant impact on their quality of life due to worsening of symptoms, risk of acute urinary …